According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy's has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2DLkCZZ
via IFTTT
0 comments:
Post a Comment